Post by Chang Sha on Sept 1, 2010 8:00:01 GMT -5
Tuesday, August 31, 2010, 6:41am PDT
Dynavax gets grant for hepatitis B work
San Francisco Business Times - by Steven E.F. Brown
Dynavax Technologies Corp. got part of a five-year, $17.6 million grant from the National Institute of Allergy and Infectious Diseases to study how people respond to a hepatitis B vaccine.
Berkeley-based Dynavax (NASDAQ: DVAX) got the money as part of the NIAID’s grant to Dr. Jacques Banchereau of the Baylor Institute of Immunology Research in Dallas. Banchereau’s laboratory is overseeing several projects, and the Dynavax deal is one of them.
Dynavax, which is developing Heplisav, a possible vaccine for protection from hepatitis B, will study the differences between people who do and don’t respond to the vaccine. The company says its vaccine is able to protect old people and those who are chronically ill – people who don’t typically respond well to vaccinations.
Dynavax gets grant for hepatitis B work
San Francisco Business Times - by Steven E.F. Brown
Dynavax Technologies Corp. got part of a five-year, $17.6 million grant from the National Institute of Allergy and Infectious Diseases to study how people respond to a hepatitis B vaccine.
Berkeley-based Dynavax (NASDAQ: DVAX) got the money as part of the NIAID’s grant to Dr. Jacques Banchereau of the Baylor Institute of Immunology Research in Dallas. Banchereau’s laboratory is overseeing several projects, and the Dynavax deal is one of them.
Dynavax, which is developing Heplisav, a possible vaccine for protection from hepatitis B, will study the differences between people who do and don’t respond to the vaccine. The company says its vaccine is able to protect old people and those who are chronically ill – people who don’t typically respond well to vaccinations.